Literature DB >> 27928322

Papillophlebitis: Treatment of Vision Loss Due To Subretinal Fluid with Intravitreal Ranibizumab.

İnci Güngör1, Gülhan Erciyes Konuk1, Yüksel Süllü1, Nurşen Arıtürk1.   

Abstract

There are no specific treatment protocols for papillophlebitis, which is basically a central retinal vein occlusion (CRVO) occurring in young adults. The present report is that of a 14-year-old girl, who presented with blurred vision in her right eye. Although her visual acuity (VA) was initially 20/20, there were venous engorgements, blurry disc margins, and a substantial collection of subretinal fluid. She was diagnosed with papillophlebitis. When, 2 weeks later, her VA had decreased to 20/200, she was administered intravitreally injected ranibizumab. One week post-injection, her VA had returned to normal (20/20) and the subretinal fluid had diminished markedly. Intravitreal ranibizumab injection appears to be an effective treatment modality for this condition.

Entities:  

Keywords:  Anti-VEGF; central retinal vein occlusion; macular oedema; papillophlebitis; ranibizumab

Year:  2014        PMID: 27928322      PMCID: PMC5123187          DOI: 10.3109/01658107.2014.954293

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  7 in total

1.  Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion.

Authors:  Vincent Daien; Sophie Navarre; Pierre Fesler; Laurence Vergely; Max Villain; Christelle Schneider
Journal:  Eur J Ophthalmol       Date:  2012-05-06       Impact factor: 2.597

Review 2.  Optic neuropathies for the neurologist.

Authors:  V A Purvin
Journal:  Semin Neurol       Date:  2000       Impact factor: 3.420

3.  [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].

Authors:  N Niederhauser; C Valmaggia
Journal:  Klin Monbl Augenheilkd       Date:  2013-04-29       Impact factor: 0.700

Review 4.  Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.

Authors:  Danny Mitry; Catey Bunce; David Charteris
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

5.  Intravitreal triamcinolone acetonide for the management of papillophlebitis and associated macular edema.

Authors:  Yo-Chen Chang; Wen-Chuan Wu
Journal:  Int Ophthalmol       Date:  2007-08-16       Impact factor: 2.031

6.  Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report.

Authors:  Hidetaka Noma; Hiroshi Shimizu; Tatsuya Mimura
Journal:  Clin Ophthalmol       Date:  2013-05-09

7.  Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion.

Authors:  Mehmet Demir; Burcu Dirim; Zeynep Acar; Yekta Sendul; Ersin Oba
Journal:  Indian J Ophthalmol       Date:  2014-03       Impact factor: 1.848

  7 in total
  1 in total

1.  Possible Association of Papillophlebitis with Guillain-Barré Syndrome: Case Report.

Authors:  Müge Çoban Karataş; Merih Soylu
Journal:  Turk J Ophthalmol       Date:  2018-09-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.